title: Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics.
abstract: We aimed to develop prognostic biomarkers for synovial sarcoma employing a proteomic approach. We examined the proteomic profile of synovial sarcoma using two-dimensional difference gel electrophoresis (2D-DIGE). We identified 20 protein spots whose intensity was statistically different (p<0.01) between a group of eight patients who were alive and continuously disease-free for over five years and a group of five patients who died of the disease within two years post diagnosis. Mass spectrometric protein identification demonstrated that these 20 spots corresponded to 17 distinct gene products. Three of the 20 spots corresponded to secernin-1 and had higher intensity in the good prognosis group. The prognostic performance of secernin-1 was further examined immunohistochemically in 45 synovial sarcoma cases. The 5-year survival rate was 77.6% and 21.8% for patients with secernin-1 positive and negative primary tumors respectively (p=0.0015). The metastasis-free survival was significantly higher in the patient group with high secernin-1 expression compared to that with low expression (p=0.0012). Uni- and multivariate analyses revealed that secernin-1 expression was a powerful prognostic factor compared to other clinico-pathological parameters examined. These results indicate that secernin-1 may be used as a biomarker to predict the overall and metastasis-free survival in synovial sarcoma patients.
authors.affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Suehara
authors.forename: Naobumi
authors.initials: N
authors.lastname: Tochigi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kubota
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kikuta
authors.forename: Robert
authors.initials: R
authors.lastname: Nakayama
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Seki
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ichikawa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kaneko
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Chuman
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Beppu
authors.forename: Akira
authors.initials: A
authors.lastname: Kawai
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kondo
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000032:analysis*; D011379:Prognosis; D040901:Proteomics; D013584:Sarcoma, Synovial / Q000473:pathology; D057825:Two-Dimensional Difference Gel Electrophoresis
chemical_list: D014408:Biomarkers, Tumor; D009419:Nerve Tissue Proteins; C471696:SCRN1 protein, human